Randomized placebo-controlled trials in the development of disease-modifying treatments for Alzheimer’s disease are typically of short duration (12–18 months), and health economic modeling requires extrapolation of treatment effects beyond the trial period.

(1) Reed, C., Happich, M., Raskin, J. et al. J Prev Alzheimers Dis (2019) 6: 90–99 https://doi.org/10.14283/jpad.2019.4

Article